A confirmatory dose-ranging study of riluzole in ALS. ALS/Riluzole Study Group-II

Neurology
L LacomblezV Meininger

Abstract

ALS is a progressive motor neuron disease with no effective treatment. The anti-excitotoxic drug riluzole (100 mg/day) has been shown to decrease mortality and muscular deterioration in ALS patients. To confirm and extend the therapeutic effect of riluzole, we performed a double-blind, placebo-controlled, multicenter, international, dose-ranging (50, 100, 200 mg/day), stratified study in 959 ALS outpatients treated for up to 18 months. Primary efficacy criterion was survival and the effect of treatment was analyzed before (Wilcoxon and log rank tests) and after adjustment on prognostic factors (Cox model). Secondary efficacy criterion was disease progression assessed through change in functional measures. Tracheostomy-free survival rates were: 50.4% (placebo), 55.3% (50 mg riluzole) (p = 0.23, Wilcoxon test; p = 0.25, log-rank test), 56.8% (100 mg riluzole) (p = 0.05, Wilcoxon test; p = 0.076, log-rank test), and 57.8% (200 mg riluzole) (p = 0.061, Wilcoxon test; p = 0.075, log-rank test). At the end of the 18-month study, there was a significant dose-related decrease in risk of death or tracheostomy (p = 0.04). Adjustment for baseline prognostic factors showed a 35% decreased risk of death with the 100-mg dose compared with pl...Continue Reading

Citations

Dec 17, 2008·Current Neurology and Neuroscience Reports·Jinsy Andrews
Nov 17, 2010·Current Neurology and Neuroscience Reports·Rebecca TraubLewis P Rowland
Oct 1, 2010·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Marcelo R Vargas, Jeffrey A Johnson
Apr 20, 2001·Journal of the Neurological Sciences·N Le ForestierV Meininger
Oct 26, 2001·Journal of the Neurological Sciences·G J GroeneveldL H van den Berg
Dec 14, 1999·Journal of the Neurological Sciences·M T DesiatoM D Caramia
Jul 25, 2000·British Journal of Pharmacology·T JehleT J Feuerstein
Oct 13, 2000·The European Journal of Neuroscience·A Urbani, O Belluzzi
Feb 5, 2009·Orphanet Journal of Rare Diseases·Lokesh C Wijesekera, P Nigel Leigh
Nov 13, 2007·Journal of Endocrinological Investigation·L L MorselliM Gasperi
Oct 23, 2013·Neurología : publicación oficial de la Sociedad Española de Neurología·U Gomez-PinedoA G García
Oct 13, 2011·Integrative and Comparative Biology·Katharina A Quinlan
Oct 21, 2011·Journal of Neurophysiology·J E SchusterC J Heckman
Jun 28, 2003·Neurotoxicity Research·Wojciech Danysz, Chris G Parsons
Jun 12, 2009·Drug Metabolism Reviews·Shu-Feng ZhouBalram Chowbay
Dec 8, 2015·Expert Opinion on Biological Therapy·Chi-Jing ChoongHideki Mochizuki
Feb 9, 2002·Movement Disorders : Official Journal of the Movement Disorder Society·Jörg MüllerWerner Poewe
Dec 6, 2011·La Presse médicale·Guillaume LehériceyPierre-François Pradat
Sep 11, 2009·Annals of Neurology·Jun MitsumotoRobert C Griggs
Jan 24, 2006·Archivos de bronconeumología·L Borderías-ClauJ L Bru-Martín
Mar 22, 2005·Lancet Neurology·Jennica M C WinhammarMatthew C Kiernan
May 26, 2009·American Journal of Ophthalmology·Helen V Danesh-Meyer, Leonard A Levin
Jun 7, 2006·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·J Douglas MitchellMiland Joshi
Sep 12, 2006·Amyotrophic Lateral Sclerosis : Official Publication of the World Federation of Neurology Research Group on Motor Neuron Diseases·Ambre PiquardLucette Lacomblez
Oct 2, 2008·Journal of the American Academy of Child and Adolescent Psychiatry·Frank P MacMasterDavid R Rosenberg
Sep 21, 2016·Expert Review of Neurotherapeutics·Stéphane MathisGwendal Le Masson
Aug 16, 2016·Muscle & Nerve·Haris HakeemSara Khan
Jun 14, 2015·Experimental Neurology·Cassandra N DennysAlvaro G Estevez
Sep 2, 2009·Arquivos de neuro-psiquiatria·Acary Souza Bulle Oliveira, Roberto Dias Batista Pereira
Jun 3, 2017·The Journal of Spinal Cord Medicine·Laureen D HachemMichael G Fehlings
Jun 3, 2008·Neuroscience Letters·Naoko Tomimatsu, Yoshihiro Arakawa
Mar 25, 2009·Experimental Neurology·Nicholas J Maragakis
Dec 16, 2016·PharmacoEconomics·Alan MooreDyfrig A Hughes
Feb 16, 2018·Frontiers in Molecular Neuroscience·Anne VejuxGérard Lizard
May 25, 2002·The New England Journal of Medicine·Jan H VeldinkLeonard H van den Berg
Jun 2, 2001·The New England Journal of Medicine·L P Rowland, N A Shneider
Oct 18, 2005·Muscle & Nerve·Thais Federici, Nicholas M Boulis
Dec 14, 2012·The Cochrane Database of Systematic Reviews·Daniel M PastulaRichard S Bedlack
Apr 25, 2006·Journal of Palliative Medicine·Ingela Nygren, Håkan Askmark

❮ Previous
Next ❯

Related Concepts

Related Feeds

Amyloid Lateral Sclerosis

Amyotrophic Lateral Sclerosis (ALS) is a progressive nervous system disease associated with the death of neurons that control voluntary muscles. Discover the latest research on ALS here.

ALS: Therapies

Amyotrophic Lateral Sclerosis (ALS) is associated with the death of neurons that control voluntary muscles. This feed followes the latest research into therapies for this progressive neurodegenerative disease.